N,N,2-三甲基-5-硝基苯磺酰胺
N,N,2-三甲基-5-硝基苯磺酰胺 性质
| 熔点 | 65-67°C |
|---|---|
| 沸点 | 391.1±52.0 °C(Predicted) |
| 密度 | 1.334±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度为12 毫克/毫升 |
| 形态 | 固体 |
| 酸度系数(pKa) | -5?+-.0.70(Predicted) |
| 颜色 | 白色 |
| 稳定性 | 从购买之日起 2 年内保持稳定。 DMSO 或乙醇溶液可在 -20℃ 下保存长达 3 个月。 |
N,N,2-三甲基-5-硝基苯磺酰胺 用途与合成方法
IC50: 0.15 μM (PDE7A), 12 μM (PDE7B), 62 μM (PDE4), 490 μM (PDE3)
BRL-50481 increases the cAMP content (19.1±6.2% of IBMX response at 300 μM) but is considerably less potent. BRL-50481 (30 μM) fails to suppress proliferation by itself but significantly potentiates the effect of rolipram. BRL-50481 (30 μM) has no effect on IL-15-induced proliferation but augments the inhibitory effect of rolipram. Pretreatment (30 min) of human monocytes with BRL-50481 has, by itself, a negligible (~2 to 10%) inhibitory effect on TNFα output at all concentrations tested. BRL-50481 also potentiates the inhibitory effect of PGE 2 on LPS-induced TNFα release. BRL-50481 has no significant effect by itself on κB-dependent transcription (5.6±1.9% inhibition at 30 μM) and fails to enhance the effect of rolipram (maximum inhibition, 52.9±2.7%; pIC 30 value of 5.33±0.12). BRL-50481 suppresses, in a concentration-dependent manner, LPS-induced TNFα release in monocytes in which PDE7A1 is induced (21.7±1.6% inhibition at 30 μM at the 12-h time point).
N,N,2-三甲基-5-硝基苯磺酰胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-109586 | N,N,2-三甲基-5-硝基苯磺酰胺 | 433695-36-4 | 5mg | 500 |
| 2024-01-25 | HY-109586 | N,N,2-三甲基-5-硝基苯磺酰胺 | 433695-36-4 | 10mM * 1mLin DMSO | 550 |
